There is no FDA-approved Semax dosage chart in the United States. Published Semax research is mostly intranasal and often from Russian clinical settings, while subcutaneous dosing has much less human evidence. Any chart should be treated as research context only, not instructions for self-use, and reviewed with a licensed clinician.
Wondering if peptide therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →| Chart item | What it can show | What it cannot tell you | Evidence context |
|---|---|---|---|
| Semax status | Semax is discussed in research as an ACTH(4-10)-derived synthetic heptapeptide. | It cannot be treated like an FDA-approved U.S. dosing schedule. | Semax review literature describes neuroactive and investigational uses 1. |
| Intranasal Semax | A nasal product may be labeled by concentration, such as mg/mL, or by mcg per spray/drop. | It cannot tell you how many sprays or drops to use without a clinician and verified product label. | Intranasal use is the route most often discussed in human clinical literature 1. |
| Subcutaneous Semax | A vial may require concentration math after reconstitution. | It cannot prove that injection protocols have the same evidence as intranasal studies. | Human injection evidence is thinner than intranasal evidence, so claims should be cautious 1. |
| mcg, mg, mL, and units | 1 mg equals 1,000 mcg. Concentration times volume gives the amount of peptide. | Unit math cannot decide whether Semax is safe or appropriate for you. | This is arithmetic, not a dosing recommendation. |
| Cycle length | Research and clinic-style protocols may describe short courses rather than indefinite use. | A chart cannot decide breaks, monitoring, or whether to stop. | Long-term safety data for Semax use in U.S. patients are limited 1. |
What is the safest way to read a Semax dosage chart?
Semax charts are safest when read as reference material, not as a plan to follow. Because there is no FDA-approved U.S. Semax dose, a chart should only help you understand terms like mcg, mg, mL, concentration, and route.
Why a chart is not a prescription
A prescription dose depends on diagnosis, medical history, medications, route, product quality, and follow-up. Semax is not FDA-approved in the United States, and dosing ranges discussed online often mix research, foreign-label, and clinic-style protocols without making that clear 1.
Why route, concentration, and label strength change the dose
Intranasal Semax may be measured as mcg per spray, mcg per drop, or mg/mL. Subcutaneous Semax may start as a lyophilized peptide vial that is mixed with bacteriostatic water, which means the final amount per mL depends on how it was reconstituted.
What is Semax, and what is it being studied for?
Semax is a synthetic heptapeptide derived from an ACTH(4-10) fragment. It is often described as a nootropic or neuroactive peptide, but research interest is not the same as an approved clinical benefit in U.S. patients 1.
Semax as a synthetic ACTH-derived heptapeptide
Semax is related to a fragment of adrenocorticotropic hormone, or ACTH. The molecule is designed to be more stable than the short native fragment, and N-acetyl Semax is a related acetylated form discussed in peptide literature 1.
How Semax differs from FDA-approved medications
FDA-approved drugs have an approved label, studied indications, manufacturing standards, and reviewed dosing instructions. Semax does not have that U.S. label, so claims about cognition, stroke recovery, migraine, trigeminal neuralgia, or longevity must be framed as investigational or research-context claims 3.
Common research areas: cerebral ischemia, cognition, stress response, and neuroinflammation
Semax has been studied for cerebral ischemia and other neurologic research areas, and mechanistic papers discuss pathways tied to immune and vascular gene expression 2. These findings do not prove that Semax improves memory, prevents neurologic disease, or extends human lifespan.
Mechanism terms can sound stronger than the evidence. BDNF, TrkB, dopamine, serotonin, neuroplasticity, neuroinflammation, the blood-brain barrier, and nasal mucosa delivery are all relevant research concepts, but they should not be read as guaranteed patient outcomes 1.
Is Semax FDA-approved or legally compounded in the United States?
Semax is not FDA-approved in the United States. On July 24, 2026, the FDA Pharmacy Compounding Advisory Committee recommended Semax for possible inclusion on the 503A Bulks List, but a PCAC vote is advisory and the FDA’s final determination is still pending 3.
FDA approval status versus research or wellness use
FDA approval answers a different question than research use. A compound can be studied in papers or discussed in wellness clinics without having an FDA-approved indication, dose, route, or patient instructions 4.
What FDA 503A bulk-drug review means and does not mean
The 503A Bulks List process concerns whether certain substances may be used by state-licensed 503A pharmacies under federal compounding rules. It does not make a peptide FDA-approved, and it does not replace patient-specific clinician review 4.
Why compounded peptides require careful regulatory and clinical review
With peptides, the safety gap is often licensed versus unlicensed sourcing. A licensed clinician and a state-licensed 503A pharmacy are different from no-prescription research-chemical vendors, where sterility, potency, identity, and handling may be unclear 5.
What Semax dosage ranges appear in published research?
Published Semax dosing is not a single U.S. dosage chart. The most useful way to read the literature is by route, formulation, and indication, with the reminder that research-context ranges are not instructions for patient use 1.
Intranasal Semax research ranges
Intranasal Semax is the route most often described in human Semax literature. Papers and summaries commonly discuss nasal delivery because the nasal mucosa may provide access to central nervous system pathways, but exact dose interpretation depends on the product concentration and spray or drop volume 1.
Injectable Semax research context and why human evidence is thinner
Subcutaneous Semax appears in clinic-style and research discussions, but direct human evidence is thinner than for intranasal use. Injection also adds sterility, reconstitution, syringe, and injection-site risks that do not apply in the same way to nasal products 6.
Why animal dosing cannot be converted into a human dose
Animal and cell studies can explain possible mechanisms, such as gene-expression changes related to immune or vascular systems, but they cannot be converted into a personal human dose 2. Species, route, metabolism, and study goals differ too much.
How do nasal spray and injection Semax dosing differ?
Intranasal Semax dosing is usually label-based, while injectable Semax requires concentration math after reconstitution. The key difference is that sprays measure delivered nasal volume, while U-100 insulin syringe units measure injected volume.
Intranasal delivery: metered sprays, drops, and concentration labels
A metered nasal spray may state mcg per spray, which is the clearest label. If it only states mg/mL, the delivered amount depends on how much liquid each spray or drop releases.
Subcutaneous injection: vial concentration, reconstitution, and unit math
An injectable peptide vial may list total peptide amount, such as mg per vial, before liquid is added. Once bacteriostatic water is added, the concentration changes based on total peptide divided by final volume.
| Feature | Intranasal Semax | Subcutaneous Semax |
|---|---|---|
| Most common evidence context | More often discussed in human Semax literature 1. | Less direct human evidence; often discussed in clinic-style protocols. |
| How amount is usually labeled | mcg per spray, mcg per drop, or mg/mL. | mg per vial, then mg/mL after reconstitution. |
| Main math issue | Spray or drop volume must be known. | Vial amount, diluent volume, and syringe units must be known. |
| Main safety issue | Nasal irritation, variable spray volume, product source. | Sterility, injection technique, dosing errors, injection-site reactions 6. |
| What a chart can do | Explain label reading. | Explain concentration and unit conversion. |
| What a chart cannot do | Choose a dose or diagnosis. | Choose a dose, route, cycle, or monitoring plan. |
How do you convert Semax mg, mcg, mL, and syringe units?
Semax conversion math starts with units, not goals. The core rule is 1 mg = 1,000 mcg, and the amount delivered equals concentration multiplied by volume.
Dosing chart slot: example math using concentration only, not a recommended dose
| Known information | Math | Result | Important note |
|---|---|---|---|
| 1 mg | 1 × 1,000 | 1,000 mcg | This is a unit conversion, not a dose. |
| 0.5 mg | 0.5 × 1,000 | 500 mcg | This does not mean 500 mcg is appropriate. |
| Concentration: 1 mg/mL; volume: 0.1 mL | 1 mg/mL × 0.1 mL | 0.1 mg, or 100 mcg | The volume per spray or injection must be verified. |
| Concentration: 2 mg/mL; volume: 0.25 mL | 2 mg/mL × 0.25 mL | 0.5 mg, or 500 mcg | Same mcg amount can come from different volumes. |
| U-100 insulin syringe: 10 units | 10 units = 0.10 mL | Amount depends on concentration | Units measure volume, not peptide strength. |
Formula: concentration multiplied by volume
The formula is: amount of peptide = concentration × volume. If concentration is in mg/mL and volume is in mL, the answer is in mg; multiply by 1,000 to convert mg to mcg.
Why syringe units measure volume, not peptide strength
On a U-100 insulin syringe, 100 units equals 1 mL. That means 10 units equals 0.1 mL, but the mcg amount still depends on the vial concentration.
Common conversion mistakes patients make
- Confusing mg and mcg. A 1 mg amount is 1,000 mcg, not 100 mcg.
- Assuming one spray always delivers the same volume across products.
- Assuming syringe units equal peptide amount. Units measure liquid volume.
- Using a reconstitution chart from one vial strength for a different vial.
- Treating a research chart as a personal protocol.
How long are Semax cycles in research and clinic-style protocols?
Semax cycle length is not standardized in the United States. Because long-term safety data are limited, continuous use should not be assumed safe or appropriate 1.
Short courses versus continuous use
Some Semax discussions describe short courses rather than open-ended use. That pattern reflects limited safety data and the fact that many studies were designed around specific neurologic questions, not lifelong wellness use 1.
Why long-term safety data are limited
A small or mixed evidence base can miss uncommon side effects, drug interactions, or risks in people with complex health histories. That is why Semax should not be presented as a proven longevity therapy.
Why breaks, monitoring, and follow-up are clinician decisions
Breaks and monitoring depend on the reason for use, other medications, blood pressure, sleep, mood history, neurologic symptoms, and adverse effects. A chart cannot safely account for all of that.
What side effects and safety issues should patients know about?
Semax safety is not fully defined for broad U.S. wellness use. Possible issues include overstimulation, headache, sleep disruption, nasal irritation, injection-site problems, and product-quality risks, with limited long-term data 1.
Possible overstimulation, headache, sleep disruption, or nasal irritation
Because Semax is studied as a neuroactive peptide, patients should take symptoms like anxiety, agitation, headache, insomnia, or unusual neurologic symptoms seriously. Nasal products can also irritate the nasal mucosa.
Injection-related risks if using subcutaneous products
Subcutaneous products add risks from needle use, contamination, and injection technique. CDC injection-safety guidance emphasizes aseptic technique, single-patient medication handling, and avoiding contamination 6.
Why purity, sterility, and source matter
Peptide identity, potency, sterility, storage, and beyond-use dating matter. FDA has warned that compounded drugs are not FDA-approved and may carry quality risks when sourcing or standards are poor 5. USP sterile-compounding standards also address contamination control for sterile preparations 7.
Who should avoid unsupervised peptide use
People who are pregnant, trying to conceive, breastfeeding, immunocompromised, managing serious neurologic symptoms, or taking psychiatric or neurologic medications should not experiment with unsupervised peptides. New weakness, facial droop, severe headache, chest pain, confusion, or trouble speaking needs urgent medical care.
Does Chia offer Semax peptide treatment?
Chia does not currently offer Semax. We cover Semax here for education because patients ask about it, but availability through Chia is limited to the treatments listed in our current catalog.
Chia does not currently offer Semax
At Chia, prescriptions require a 100% online health questionnaire and review by a licensed U.S. provider, and a prescription is never guaranteed. For treatments we do offer, medications are compounded by state-licensed U.S. 503A pharmacies and shipped to the patient’s door.
How Chia approaches peptide education and clinician-reviewed care
Our peptide care focuses on treatments in our live catalog, including NAD+, glutathione, and sermorelin. We also offer multi-treatment protocols such as Foundation Longevity, but these should not be treated as substitutes for Semax.
Chia treatments that are available today should not be treated as substitutes for Semax
Different peptides have different structures, mechanisms, evidence bases, risks, and regulatory status. If your question is specifically about Semax, the right next step is a clinician discussion about your goals and symptoms, not swapping in another peptide on your own.
What should you ask a clinician before considering Semax?
Before considering Semax, ask whether your symptom needs diagnosis first. A clinician should review route, source, safety, interactions, and monitoring before any investigational peptide is considered.
Questions about diagnosis, goals, route, product source, and monitoring
- What condition or goal is being addressed, and is there a better-studied option?
- Is the evidence human, animal, or cell-based?
- Is the proposed route intranasal or subcutaneous, and why?
- What pharmacy or source is being used, and how are sterility and potency checked?
- What side effects should lead to stopping and contacting a clinician?
Questions about drug interactions and medical history
Bring a full medication and supplement list. Semax discussions often involve neurotransmitter terms like dopamine and serotonin, so psychiatric history, sleep disorders, neurologic history, blood pressure, and stimulant use all matter 1.
When to seek urgent medical care instead of using a peptide
Do not use a peptide chart to manage stroke-like symptoms, severe migraine changes, sudden weakness, vision loss, chest pain, fainting, or confusion. Those symptoms need urgent medical evaluation.
There is no FDA-approved typical Semax nasal spray dose for U.S. patients. Published Semax literature most often discusses intranasal use, but the amount depends on formulation, concentration, spray or drop volume, and study context.
There is no FDA-approved typical Semax injection dose. Subcutaneous Semax has less direct human evidence than intranasal Semax, and vial concentration and reconstitution can change the amount delivered per syringe unit.
1 mg equals 1,000 mcg. That conversion is basic unit math and does not mean that 1 mg, or any other amount, is appropriate for a person to use.
You cannot know from mcg alone. Syringe units measure volume, not peptide strength. To calculate it, you need the final concentration after reconstitution, then divide the desired amount by that concentration.
No. A Semax dosage chart can help you understand terms and math, but it cannot diagnose you, check interactions, verify product quality, or choose a safe dose.
No. Semax is not FDA-approved in the United States. It does not have an FDA-approved indication, route, dose, or patient dosing chart.
Semax was recommended by PCAC for possible 503A Bulks List inclusion in July 2026, but that recommendation is not a final FDA listing. Legal status can change, so current FDA and state-board guidance should be checked.
No. Chia does not currently offer Semax. Chia does offer other clinician-reviewed treatments in its live catalog, but those should not be treated as substitutes for Semax.
References
- 1.The Potential of the Peptide Drug Semax and Its Derivative for Clinical and Experimental Use. 2025.
- 2.Dergunova LV, Filippenkov IB, Stavchansky VV, et al. The peptide Semax affects the expression of genes related to the immune and vascular systems in human cells. BMC Genomics. 2014.
- 3.U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. 2026.
- 4.U.S. Food and Drug Administration. Compounding Laws and Policies. 2026.
- 5.U.S. Food and Drug Administration. Understanding the Risks of Compounded Drugs. 2026.
- 6.Centers for Disease Control and Prevention. Injection Safety. 2024.
- 7.United States Pharmacopeia. USP General Chapter <797>: Pharmaceutical Compounding—Sterile Preparations. 2023.
- 8.U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if peptide therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
